TKPHF - Takeda Pharmaceutical Company Limited
| Previous close | 32.05 |
| Open | 32.05 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 32.05 - 32.05 |
| 52-week range | 25.07 - 34.47 |
| Volume | |
| Avg. volume | 49,883 |
| Market cap | 50.259B |
| Beta (5Y monthly) | 0.68 |
| PE ratio (TTM) | 22.10 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.39 (4.34%) |
| Ex-dividend date | 28 Sept 2023 |
| 1y target est | N/A |
- Zacks
Reasons to Add Puma (PBYI) Stock to Your Portfolio Right Now
Puma Biotechnology (PBYI), a top-ranked stock, has a promising development candidate, alisertib. Its only marketed product, Nerlynx (neratinib), is witnessing improving demand trends in the United States.
- Zacks
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- Zacks
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- Motley Fool
2 Incredibly Cheap High-Yield Dividend Stocks to Buy Now
High-yield dividend stocks can be a great way to protect your portfolio from market volatility. Read on to find out more about these two high-yield dividend stocks. Ford, and most of its contemporaries, took a big step backward last year over concerns about the impact of rising interest rates on demand for new vehicles.
- Zacks
Is Grifols (GRFS) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- Motley Fool
Is This the Telltale Sign to Sell Novavax Stock?
Unfortunately, Novavax (NASDAQ: NVAX) hasn't had great timing. The company was late to the party in winning authorizations for its COVID-19 vaccine, Nuvaxovid. If you only looked at Novavax's press releases, you wouldn't know about some recent bad news for the company.
- Reuters
Japan's Takeda's profit slips 13%, pipeline bolsters outlook
Japan's Takeda Pharmaceutical Co posted a 13% drop in operating earnings for the nine months ended December but kept its profit outlook for the fiscal year unchanged as it works to bolster its drugs pipeline. Takeda's annual operating profit forecast of 530 billion yen already lags a Refinitiv analysts' consensus forecast of 593.9 billion yen. European Union regulators in December approved Takeda's vaccine for dengue fever, branded as QDENGA.
- Reuters
Slumping China-bound Japanese exports raise fears of global downturn
Japan's export growth slowed sharply in December as China-bound shipments fell for the first time in seven months, stoking fears of further slowdown in the global economy and external demand for Japanese shipments. Exports rose 11.5% year-on-year in December after a gain of 20% in November, marking the slowest growth since the start of 2022, dragged down by a fall-off in sales to China of cars, auto parts and chip-making machinery, Ministry of Finance (MOF) data showed on Thursday. Exports to largest trading partner China fell 6.2% year-on-year in value and were down 24% in volume terms in December.
- Motley Fool
Why Puma Biotechnology's Shares Jumped 20% on Monday
The biopharmaceutical company specializes in cancer therapies. Its stock got a boost on Monday when a Takeda Pharmaceutical (NYSE: TAK) candidate, ponatinib, hit its primary goal in a phase 3 clinical trial as a treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia. The blood cancer therapy works by slowing the activity of BCR-ABL1, a gene sequence found in an abnormal chromosome 22, often seen in people with certain types of leukemia.
- Motley Fool
2 Beaten-Down Dividend Stocks That Haven't Been This Cheap In More Than a Decade
Are these a couple of rare opportunities that investors shouldn't pass up, or are the price drops valid because of significant concerns that should keep you away from these companies? Takeda is a Japan-based healthcare company that makes vaccines and pharmaceutical products.
- Motley Fool
3 High-Yielding Dividend Stocks Near Their 52-Week Lows
One happy consequence of a bear market is that dividend yields rise as stock prices fall. Three beaten-up stocks trading near their 52-week lows that could be especially attractive right now include Takeda Pharmaceuticals (NYSE: TAK), Duke Energy (NYSE: DUK), and Home Depot (NYSE: HD). Japanese drugmaker Takeda Pharmaceuticals is a leading healthcare company that makes vaccines and products addressing multiple therapeutic areas, including cancer, rare diseases, gastroenterology, and hematology.
- Zacks
TAK vs. ZTS: Which Stock Should Value Investors Buy Now?
TAK vs. ZTS: Which Stock Is the Better Value Option?
- Zacks
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib
Puma Biotechnology (PBYI) inks license agreement with Japan's Takeda Pharmaceuticals, gaining worldwide development and commercialization rights to the latter's cancer treatment alisertib.
- Zacks
Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- Motley Fool
Got $5,000? These 2 Dividend Stocks Haven't Been This Cheap in Years
When dividend stocks dip in price and go on sale, they can create buying opportunities for long-term investors. Takeda Pharmaceuticals (NYSE: TAK) and Verizon Communications (NYSE: VZ) are both at multi-year lows, and here's why they could be attractive options for a $5,000 investment. Takeda Pharmaceuticals is one of the largest drug companies in the world.
- Zacks
TAK or ZTS: Which Is the Better Value Stock Right Now?
TAK vs. ZTS: Which Stock Is the Better Value Option?
- Zacks
Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- Zacks
TAK vs. ZTS: Which Stock Is the Better Value Option?
TAK vs. ZTS: Which Stock Is the Better Value Option?
- Zacks
Wall Street Analysts See a 26% Upside in Takeda Pharmaceutical Co. (TAK): Can the Stock Really Move This High?
The consensus price target hints at a 26.4% upside potential for Takeda Pharmaceutical Co. (TAK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- Motley Fool
What's Winning in 2022? 3 Stocks That Are Doing Fine
It's been an ugly year in the stock market in 2022, and most investors are deep in the red. For instance, Immunocore (NASDAQ: IMCR) investors just had a U.S. Food and Drug Administration (FDA) approval, and that stock has shot higher with a 30% gain this year. Will Axsome Therapeutics (NASDAQ: AXSM) be the next stock to pop?
- Motley Fool
2 Best High-Yield Dividend Stocks to Buy Right Now
Dividend stocks are a great way to navigate volatile markets. History has shown that companies with solid balance sheets, diverse revenue streams, and a rich tradition of increasing annual distributions to shareholders tend to be the best vehicles when it comes to staving off the negative effects of economic downturns. With this insight in mind, my top two dividend stocks to buy right now are Icahn Enterprises (NASDAQ: IEP) and Takeda Pharmaceutical Company (NYSE: TAK).
- Reuters
Takeda, Nintendo among Japanese firms quietly celebrating weak yen
Japan's yen is at its weakest in decades and inflicting high costs of imported food and fuel on households and businesses, but also proving to be an unexpected tailwind for multinationals such as pharmaceutical giant Takeda. As the Bank of Japan reiterated its commitment to loose monetary policy on Friday, affirming its position as a standalone dove in a global environment of rising inflation, the yen edged back towards the 135.60-per-dollar lows it struck this week. Nearly half of companies that responded to a Tokyo Shoko Research poll this week said the weaker yen would have a negative impact on their businesses.
- Motley Fool
Want Loads of Passive Income? Avoid These 3 (Very) Tempting Mistakes
Dividend stocks are just as prone as other stocks to underperforming the market and doing pretty much everything except what you want them to do -- increase and pay out. The catch is that some of the worst dividend investing mistakes are disguised as being juicy opportunities. Let's go over three of the most tempting and most destructive foibles so that you'll be protected against them when you're figuring out which passive income stocks are worth your money.
- Yahoo Finance
FDA advisory committee recommends Novavax vaccine for use in adults
FDA votes to recommend use of Novavax COVID-19 vaccine in adults
